ProPhase Labs (NASDAQ:PRPH) Upgraded to “Sell” at StockNews.com

StockNews.com upgraded shares of ProPhase Labs (NASDAQ:PRPH) to a sell rating in a research note published on Wednesday morning.

ProPhase Labs Stock Down 1.4 %

NASDAQ:PRPH opened at $4.26 on Wednesday. ProPhase Labs has a 12-month low of $4.05 and a 12-month high of $7.59. The company has a quick ratio of 1.73, a current ratio of 1.88 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $81.28 million, a P/E ratio of -3.94 and a beta of -0.18. The stock’s fifty day simple moving average is $4.92 and its 200-day simple moving average is $5.10.

ProPhase Labs (NASDAQ:PRPH) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.21. ProPhase Labs had a negative return on equity of 44.96% and a negative net margin of 82.18%. The business had revenue of $3.63 million for the quarter, compared to analyst estimates of $9.86 million. During the same period last year, the company earned $0.03 EPS. Equities research analysts expect that ProPhase Labs will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PRPH. Tower Research Capital LLC TRC lifted its holdings in ProPhase Labs by 50.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock worth $68,000 after acquiring an additional 5,026 shares in the last quarter. HighTower Advisors LLC bought a new position in ProPhase Labs during the third quarter worth about $756,000. Finally, Vanguard Group Inc. lifted its holdings in ProPhase Labs by 1.5% during the first quarter. Vanguard Group Inc. now owns 618,763 shares of the company’s stock worth $4,003,000 after acquiring an additional 9,416 shares in the last quarter. 9.45% of the stock is currently owned by institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.